September 2018

Boston Scientific Corporation Acquires Augmenix Inc. in up to $600 Million Deal

Asia | Asia - Japan | North America - United States | Europe | Europe - United Kingdom | North America | United States - Massachusetts

Boston Scientific Corporation acquired Augmenix Inc., a privately held developer of a novel therapy to reduce side effects from radiation aimed at the prostate. Faegre Baker Daniels represented Boston Scientific in the transaction. The transaction consists of an upfront cash payment of $500 million, and up to $100 million for reaching sales-based milestones.

Read Boston Scientific's press release for more information on the deal.

Services & Industries

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.